This dataset, published on PDAPS.org, is cross-sectional and displays key features of state laws increasing access to buprenorphine and methadone during COVID-19 across all 50 states and the District of Columbia approved as of June 1, 2021.
This dataset is cross-sectional and displays key features of state Medicaid Waivers addressing COVID-19 across all 50 states and the District of Columbia approved as of July 1, 2021.
Unintentional drug overdose is a leading cause of preventable death in the United States. Administering naloxone hydrochloride (“naloxone”) can reverse an opioid overdose and prevent unintentional death. Since 2001, states have enacted naloxone laws to increase access, simplify prescribing and dispensing by health care providers, and encourage its use by individuals in a position to assist a person experiencing a drug overdose.